Table 2:

Patient factors associated with erlotinib treatment (univariate analyses).

	Entire cohort		Had genetic test		No genetic test
	Treated with erlotinib (N (%))	P-value	Treated with erlotinib (N (%))	P-value	Treated with erlotinib (N (%))	P-value
SES Variables
Income		0.0131 *		0.5622		0.1282
Low income	523 (12.4)		73 (22.9)		450 (11.6)
Not low income	804 (14.1)		177 (24.6)		657 (12.6)
High-poverty location		.0002 *		0.6300		0.0026 *
High-poverty	646 (12.2)		102 (23.2)		544 (11.2)
Not high-poverty	622 (14.8)		136 (24.6)		486 (13.3)
Demographic and Clinical Characteristics
Sex		<.0001 *		0.0178 *		<.0001 *
Female	807 (16.1)		158 (26.8)		649 (14.6)
Male	520 (10.7)		92 (20.4)		428 (9.7)
Race		<.0001 *		0.0004 *		<.0001 *
White	966 (12.1)		189 (22.0)		777 (11.0)
Black**	88 (8.8)		<11 (<20.8)		>77 (>8.1)
Asian	169 (33.9)		28 (37.8)		141 (33.2)
Hispanic**	33 (16.8)		<11 (<73.3)		>22 (>12.2)
Other or unknown	71 (29.0)		17 (43.6)		54 (26.2)
Histology		<.0001 *		0.1359		<.0001 *
Adenocarcinoma	868 (16.9)		198 (25.2)		670 (15.4)
Other non-small cell	459 (9.6)		52 (20.6)		407 (9.0)
Age at diagnosis		0.1351		0.1615		0.1736
Under 75	596 (12.9)		118 (22.2)		478 (11.7)
75 or older	731 (13.9)		132 (25.9)		599 (12.6)
Urban location		<.0001 *		0.0051 *		0.0061 *
Urban	1143 (13.9)		228 (25.1)		915 (12.5)
Not urban**	127 (9.8)		<11 (<12.8)		>116 (>9.6)
Diagnosis year		0.0002 *		<.0001 *		<.0001 *
2007	298 (15.4)		14 (45.2)		284 (15.0)
2008	270 (14.0)		23 (37.7)		247 (13.2)
2009	291 (14.6)		60 (33.0)		231 (12.8)
2010	233 (11.4)		70 (22.5)		163 (9.4)
2011	235 (11.7)		83 (18.4)		152 (9.8)
Charlson index		0.0088 *		0.0088 *		<.0001*
0	26 (15.8)		126 (28.8)		419 (16.1)
1	32 (22.7)		66 (23.3)		332 (12.4)
2	66 (23.3)		32 (22.7)		148 (10.0)
3+	126 (28.8)		26 (15.7)		160 (8.4)

^*= Significant at the 0.05 level

^**= Data masked to comply with SEER-Medicare policy regarding cells <11